APA (7th ed.) Citation

Eichenauer, D. A., & Meißner, J. (2017). Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: Final analysis of a phase 2 randomised trial by the German Hodgkin Study Group. The lancet. Oncology, 18(12), . https://doi.org/10.1016/S1470-2045(17)30696-4

Chicago Style (17th ed.) Citation

Eichenauer, Dennis Alexander, and Julia Meißner. "Incorporation of Brentuximab Vedotin into First-line Treatment of Advanced Classical Hodgkin's Lymphoma: Final Analysis of a Phase 2 Randomised Trial by the German Hodgkin Study Group." The Lancet. Oncology 18, no. 12 (2017). https://doi.org/10.1016/S1470-2045(17)30696-4.

MLA (9th ed.) Citation

Eichenauer, Dennis Alexander, and Julia Meißner. "Incorporation of Brentuximab Vedotin into First-line Treatment of Advanced Classical Hodgkin's Lymphoma: Final Analysis of a Phase 2 Randomised Trial by the German Hodgkin Study Group." The Lancet. Oncology, vol. 18, no. 12, 2017, https://doi.org/10.1016/S1470-2045(17)30696-4.